TrialInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2024

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

Domenica Lorusso et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.